Liraglutide, the glucagon‐like peptide‐1 receptor agonist, has anabolic bone effects in diabetic Goto‐Kakizaki rats 利拉鲁肽，一种胰高血糖素样肽‐1受体激动剂，在糖尿病Goto‐Kakizaki大鼠中具有骨合成代谢作用

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 4, 2015-07 ,pp. : 584-588

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 3, 2015-03 ,pp. : 555-559

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of duodenal‐jejunal bypass

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 2, 2015-02 ,pp. : 308-315

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 974-983

John Wiley & Sons Inc

Access to resources Recommend Favorite